
    
      The aim of this study is;

      To evaluate the efficacy and safety of ombitasvir, paritaprevir, and ritonavir based therapy
      for chronic hepatitis C with or without compensated cirrhosis in HCV treatment na√Øve patients
      receiving long-term haemodialysis through assessment of:

        1. The proportion of patients with a sustained virological response (HCV RNA <25 IU/mL) 12
           weeks after the last dose of study drug (SVR12).

        2. To determine withdrawal rate related to side effects and /or adverse effects for
           patients receiving at least 1 dose of the study medication.
    
  